| Male |
Upregulated |
Sphingolipid signaling pathway |
0.000462 |
7 |
| Biosynthesis of amino acids |
0.001856 |
5 |
| Hepatocellular carcinoma |
0.003485 |
7 |
| Autophagy |
0.003942 |
6 |
| NOD-like receptor signaling pathway |
0.014277 |
6 |
| Downregulated |
Rheumatoid arthritis |
0.000121 |
5 |
| Chemokine signaling pathway |
0.003538 |
5 |
| Human cytomegalovirus infection |
0.007385 |
5 |
| Cytokine-cytokine receptor interaction |
0.021566 |
5 |
| Female |
Upregulated |
Leishmaniasis |
0.000008 |
11 |
| Osteoclast differentiation |
0.000076 |
13 |
| Chemokine signaling pathway |
0.000105 |
16 |
| Renal cell carcinoma |
0.000148 |
9 |
| Hepatitis B |
0.000252 |
13 |
| Systemic lupus erythematosus |
0.000437 |
12 |
| Kaposi sarcoma-associated herpesvirus infection |
0.000937 |
14 |
| Autophagy |
0.001133 |
11 |
| Human immunodeficiency virus 1 infection |
0.001169 |
15 |
| Phagosome |
0.001433 |
12 |
| Downregulated |
Natural killer cell mediated cytotoxicity |
3.85E-07 |
13 |
| Antigen processing and presentation |
0.000366 |
7 |
| Graft-versus-host disease |
0.000680 |
5 |
| Th1 and Th2 cell differentiation |
0.001076 |
7 |
| NF-kappa B signaling pathway |
0.001300 |
7 |
| T cell receptor signaling pathway |
0.001856 |
7 |
| Sphingolipid signaling pathway |
0.004458 |
7 |
| Hematopoietic cell lineage |
0.006826 |
6 |
| HIF-1 signaling pathway |
0.007894 |
6 |
| Overlap |
Upregulated |
Platelet activation |
0.000410 |
5 |
| Downregulated |
Structural constituent of ribosome |
0.000097 |
6 |
| DNA-binding transcription activator activity, RNA polymerase II-specific |
0.001188 |
8 |
| RNA polymerase II proximal promoter sequence-specific DNA binding |
0.002694 |
8 |
| proximal promoter sequence-specific DNA binding |
0.003296 |
8 |
